Skip to main content

Master of Public Health

Genomic Profiling of T-Cell Neoplasms Reveals Frequent and Mutations With Clonal Evasion From Targeted Therapies.

AUTHORS

Greenplate A , Wang K , Tripathi RM , Palma N , Ali SM , Stephens PJ , Miller VA , Shyr Y , Guo Y , Reddy NM , Kozhaya L , Unutmaz D , Chen X , Irish JM , Davé UP , . JCO precision oncology. 2018 ; 2018().

ABSTRACT

The promise of precision oncology is that identification of genomic alterations will direct the rational use of molecularly targeted therapy. This approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, like T-cell leukemias and lymphomas. In this study, we tested the feasibility of targeted next-generation sequencing in profiles of diverse T-cell neoplasms and focused on the therapeutic utility of targeting activated JAK1 and JAK3 in an index case.

The promise of precision oncology is that identification of genomic alterations will direct the rational use of molecularly targeted therapy. This approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, like T-cell leukemias and lymphomas. In this study, we tested the feasibility of targeted next-generation sequencing in profiles of diverse T-cell neoplasms and focused on the therapeutic utility of targeting activated JAK1 and JAK3 in an index case.

Tags: